Key result
Troponin I demonstrated the highest sensitivity among the evaluated cardiac biomarkers, with abnormal levels detected in 81.4% of patients experiencing their first episode of acute myocardial infarction.
Why the study?
Existing diagnostic tools historically were not beneficial for risk prediction, prompting the need to compare biochemical markers for early diagnosis and high diagnostic sensitivity and specificity in acute myocardial infarction.
Population
140 individuals with AMI diagnosed using WHO criteria
Comparison
Diagnostic sensitivity and specificity across various biochemical markers
Design
Cross-sectional study with purposive sampling
Authors
Loading...
May support Troponin I prioritization in early AMI; cross-sectional data leave open prospective outcome validation.
Cross-Sectional (n=140)
No
In patients presenting with early acute myocardial infarction and abnormal ECG, Troponin I is the most frequently elevated biochemical marker compared to traditional cardiac enzymes.
Sohaib et al. (2022) conducted a cross-sectional in Acute Myocardial Infarction (AMI) (n=140). Cardiac biomarkers (Troponin I) vs. Other cardiac biomarkers (LDH, D-Dimer, CK-MB, AST, NT-Pro-BNP, Troponin T, CPK) was evaluated on Abnormal biomarker levels in AMI patients. Troponin I demonstrated the highest sensitivity among the evaluated cardiac biomarkers, with abnormal levels detected in 81.4% of patients experiencing their first episode of acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: